Ebola Vaccine Hailed As 'Game Changer' In Fight Against The Virus
Doctors Without Borders is calling it a "champagne moment." The World Health Organization says it's a "game changer."
In a small trial, an experimental vaccine protected 100 percent of participants who were at high risk for the virus. Although the results are preliminary, they offer new hope of finally stamping out the virus in West Africa — and preventing the next epidemic.
"It is a game changer because there was nothing that could protect people against Ebola — no drug, vaccine or medicine," says Dr. Marie-Paule Kieny, assistant director-general for health systems and innovation at the World Health Organization, who helped to lead the trial. "This is the very first intervention against Ebola."
The vaccine, called rVSV-ZEBOV, was developed by the Public Health Agency of Canada. Previous studies showed it was safe. In April, WHO and Doctors Without Borders started testing its effectiveness in Guinea. The trial is ongoing, but the team published initial results Friday in The Lancet.
The vaccine stops Ebola in its tracks, Kieny says.
"When we talked with our colleagues who are responding to Ebola [cases], they told us, 'It's strange. There are many cases in a community. And we vaccinate, and the cases seem to disappear.' "
In fact, there are so few cases in Guinea right now that Kieny and her team couldn't use the standard method for testing a vaccine. The team had to come up with a whole new design for the trial. The strategy uses what's called ring vaccination.
When a case crops up, the team rushes to scene and
gives the vaccine to people who are close to the sick person — those who are at high risk of getting the virus.
"So this can be the neighbors, the family, the coworkers," Kieny says. "This forms what is called a ring. These are the people that form the community around the case."
Over the past few months, Kieny and her team identified about 4,000 people in these so-called rings who were eligible for vaccination. They divided them up into two groups. About half got vaccinated immediately, and the others had to wait three weeks for the shot.
The results were striking. In the group that got the vaccine immediately, no one got Ebola.
"No cases at all. Zero," Kieny says. "So this provides an estimate of efficacy of 100 percent!"
That sounds amazing — even unbelievable. And it actually is, Kieny says.
The problem is there were only 16 cases of Ebola in the group that didn't get the vaccine immediately. That's way too small of a number to say how well the vaccine works, she says.
But statistical analyses suggest the vaccine's efficacy is at least 70 percent, Kieny says — which is still good enough to stop the spread of the disease.
"I think it is very encouraging to see these very positive, preliminary results of this vaccine trial from Guinea," says Dr. Jesse Goodman, an infectious disease specialist at Georgetown University, who once led vaccine development at the U.S. Food and Drug Administration.
Goodman says we need to be cautious about the study. More data are needed to nail down the vaccine's efficacy. And there were a few issues with the design of the experiment that could have skewed the results.
"But nonetheless," he says, "the strength of the difference between the groups that were vaccinated early and late suggests strongly to me that this vaccine is working."
9(MDE1MTIxMDg0MDE0MDQ3NTY3MzkzMzY1NA001))
Transcript
AUDIE CORNISH, HOST:
It's a champagne moment in the fight against Ebola, according to Doctors without Borders. In a small trial, an experimental vaccine protected 100 percent of the people at high risk for the virus. The results are preliminary, but the study offers new hope of wiping out Ebola in West Africa. NPR's Michaeleen Doucleff has this report.
MICHAELEEN DOUCLEFF, BYLINE: When Ebola exploded last summer, scientists around the world all agreed on one thing. To stop this epidemic quickly, we need a vaccine. Dr. Marie-Paule Kieny, an assistant director general at the World Health Organization, says they may have just reached that goal.
MARIE-PAULE KIENY: It is a game changer because there was nothing -nothing - against Ebola that could protect the people. This is the very first intervention against Ebola.
DOUCLEFF: The vaccine was developed by the Canadian Public Health Agency, and Kieny has been leading a clinical trial in Guinea since last April. She and her team published the results of that trial this week in The Lancet. She says the vaccine is safe and stops the virus in its tracks.
KIENY: When we discussed with our colleagues who are doing the response to Ebola, they told us it's strange. There are cases, cases, cases in this community, then we vaccinate, and the cases seem to disappear.
DOUCLEFF: In fact, there are so few cases in Guinea that Kieny and her team couldn't use the standard method for testing a vaccine. The team had to come up with a whole new design for the trial. The strategy uses what's called ring vaccination. When a case crops up, the team rushes to the sick person, then they give the vaccine to the people who are high risk of getting Ebola - those who are close to the sick person.
KIENY: So this can be the neighbors, the family, the co-workers. So this forms what is called a ring. These are the people who are from the community around the case.
DOUCLEFF: Over the past few months, the team identified about 4,000 people in these so-called rings. They divided them up into two groups. Half got vaccinated immediately, and the others had to wait three weeks to get the shot. The results were striking. In the group that got vaccinated immediately, no one got Ebola.
KIENY: No cases anymore - finished, zero. So this provides an estimate of efficacy, of course, of a hundred percent.
DOUCLEFF: Which sounds amazing, even unbelievable, and Kieny says it actually is. The problem is there were only 16 cases of Ebola in the group that didn't get the vaccine right away. That's way too small of a number to say for sure how well the vaccine works, but Kieny thinks its efficacy is probably closer 70 percent. Dr. Jesse Goodman, an infectious disease researcher at Georgetown University, says that's still good enough to stop the spread of the disease.
JESSE GOODMAN: I think it is very encouraging to see these very positive preliminary results of this vaccine trial from Guinea. Yes, absolutely.
DOUCLEFF: Goodman once led vaccine development of the U.S. Food and Drug Administration, and he says we need to be a bit cautious. Much more data are needed, and a few changes in the design of the study could have skewed the results.
GOODMAN: But nonetheless, the strength of the difference between the groups that were vaccinated early and late suggests strongly to me that this vaccine is working.
DOUCLEFF: Which is fantastic news, not only for finally stopping the current epidemic, but also for preventing the next one. Michaeleen Doucleff, NPR News. Transcript provided by NPR, Copyright NPR.
300x250 Ad
300x250 Ad